in Bethesda, MD, is a component of USU and is charged with executing medical radiological defense research for the Department of Defense.
The DTRA contracts to the Company and AFRRI
will provide necessary financial resources to complete collaborative evaluation of efficacy, toxicity, pharmacokinetics, and immunogenicity of a single application of Protectan CBLB502 in rodents and non-human primates.
Director of the AFRRI, stated, "This project will allow expansion of our research.
Under this initial CRADA, Humanetics is collaborating with AFRRI researchers to develop a compound to support immune function and to explore the potential benefits for military personnel.
This led to the design and implementation of a unique joint research program within the AFRRI to screen, test and develop several nutritional supplements that have such potential.
Humanetics is currently collaborating with AFRRI
and HJF to develop a pipeline of safe, low-cost oral countermeasures for ARS.
During 2005, Humanetics and AFRRI
pursued a number of oral countermeasures, many of which have been shown effective in increasing survival in mice receiving otherwise lethal doses of radiation.
AFRRI, in Bethesda, Maryland, is part of the Uniformed Services University of the Health Sciences (USU), a Congressionally-chartered, fully-accredited, graduate education university operated by the Department of Defense.
A Cooperative Research and Development Agreement (CRADA), has been entered into with USU and HJF for Humanetics to collaborate with AFRRI, the nation's premier center for radiation injury countermeasure research, and with the F.